Expertise

July 2021 - The out-licensing of Japanese rights has long been a way for smaller biopharma companies to accelerate their entry into Japan while also generating cash to fund their businesses in the U.S., Europe, and other “core” markets. Emerton has analyzed a sample of over 300 out-licensing deals to help our clients better understand typical terms, structure, and partnering trends in Japan.

May 2021 - The first round of CEA results signal change for the pharmaceutical and medical device industries in the world’s third largest market

The market for orphan drugs has experienced robust growth. However, payor reliance on siloed annual budgeting processes threatens the future of the industry and pressure is increasing due to mounting COVID-19 budget deficits. Who will break the mold and lead the charge toward a sustainable system?

The pipeline of therapeutic radiopharmaceuticals is growing and several clinical stage drugs have recently entered the market. These new therapies offer the potential to upset the oncology landscape by establishing therapeutic radiopharmaceuticals as a tool in the arsenal against cancer.

Major medical device companies are placing big bets on robotic surgery, but confusing clinical and economic outcomes have undermined confidence in the industry. How should the industry innovate to ensure its long-term success?